New cell therapy combo takes on deadly brain cancer
NCT ID NCT00807027
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested whether adding a cell therapy called Immuncell-LC to standard chemotherapy (temozolomide) helps people with newly diagnosed glioblastoma, an aggressive brain cancer. The study enrolled 180 patients in Korea who had surgery for glioblastoma. Researchers measured how long patients lived without the cancer getting worse and overall survival. The goal was to see if the combination is more effective than chemotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immuncell-LC (activated T lymphocytes) plus temozolomide
What this could lead to
If successful, this combination could improve progression-free survival and overall survival for people with newly diagnosed glioblastoma.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely confirmed. Glioblastoma is very aggressive, and even positive findings may offer only modest benefit. Risks include side effects from chemotherapy and the cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gyunghee University Medical Center
Seoul, South Korea
-
Hanyang University Guri Hospital
Guri-si, Gyeonggi-do, South Korea
-
Konkuk University
Seoul, South Korea
-
Korea University Anam Hospital
Seoul, South Korea
-
Samsung Seoul Medical Center
Seoul, South Korea
-
Seoul Asan Medical Center
Seoul, South Korea
-
Yeonsei University Medical Center
Seoul, South Korea